IL17A and chronic inflammatory demyelinating polyradiculoneuropathy: A study using this model to examine CIDP-like pathology has demonstrated that Lewis rats immunized to develop EAN and treated with intranasal IL-17 for six days following disease onset, had worse disease at peak in a dose-dependent manner; however, they had a shorter disease duration than untreated EAN rats [123].